Advertisement

Topics

PubMed Journals Articles About "Innovator Award Leukemia Immunotherapies" RSS

17:51 EST 15th November 2018 | BioPortfolio

Innovator Award Leukemia Immunotherapies PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Innovator Award Leukemia Immunotherapies articles that have been published worldwide.

More Information about "Innovator Award Leukemia Immunotherapies" on BioPortfolio

We have published hundreds of Innovator Award Leukemia Immunotherapies news stories on BioPortfolio along with dozens of Innovator Award Leukemia Immunotherapies Clinical Trials and PubMed Articles about Innovator Award Leukemia Immunotherapies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Innovator Award Leukemia Immunotherapies Companies in our database. You can also find out about relevant Innovator Award Leukemia Immunotherapies Drugs and Medications on this site too.

Showing "Innovator award leukemia immunotherapies" PubMed Articles 1–25 of 1,300+

2018 ISCB Innovator Award recognizes M. Madan Babu.


Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia.

Rust never sleeps: The continuing story of the Iron Bolt.

Since 1981, Gordon Research Conferences have been held on the topic of Oxygen Radicals on a biennial basis, to highlight and discuss the latest cutting edge research in this area. Since the first meeting, one special feature of this conference has been the awarding of the so-called Iron Bolt, an award that started in jest but has gained increasing reputation over the years. Since no written documentation exists for this Iron Bolt award, this perspective serves to overview the history of this unusual award, ...


Pediatric Cancer Immunotherapy: Opportunities and Challenges.

Cancer immunotherapies, widely heralded as transformational for many adult cancer patients, are becoming viable options for selected subsets of pediatric cancer patients. Many therapies are currently being investigated, from immunomodulatory agents to adoptive cell therapy, bispecific T-cell engagers, oncolytic virotherapy, and checkpoint inhibition. One of the most exciting immunotherapies recently FDA approved is the use of CD19 chimeric antigen receptor T cells for pre-B-cell acute lymphoblastic leukemia...

Acta Award to Regensburg.

While consuming another solemn sandwich lunch in front of your monitor, why not let your thoughts wander off to a daydream wherein you just won $100,000? This dream just became true for researchers in Regensburg!. For the first time, the recipients of the first-ever Acta Physiologica Award have been selected for the Acta Physiologica Award. Getting there, panning out the biggest nugget, was a challenge and a thrill to every selection committee member. We had a short list of 15 articles, which have been high...

Toxicities with targeted therapies after immunotherapy in metastatic melanoma.

Over the last decade, melanoma treatment has taken rapid strides with the advent of immunotherapies and targeted agents. With these new agents, there has been a significant improvement in patient survival. However, these new treatment options may sometimes lead to unanticipated side effects that make these treatments challenging to administer and monitor. In preclinical studies, BRAF and MEK inhibitors have shown to modulate tumor microenvironment and potentiate immunotherapies. Therefore, some patients who...

Transformation from promyelocytic leukemia with t (15; 17) ( q22; q21) to acute monocytic leukemia with t (11; 17) (q23; q21) in a case.

To report on a case of therapy-related acute monocytic leukemia(t-AML) with t(11;17) (q23;q21)/MLL-AF17q after successful treatment for acute promyelocytic leukemia(APL) with t(15;17) (q22;q21)/PML-RARα.

PRESENTATION OF THE ASHTON CUCKLER NEW INVESTIGATOR AWARD TO DR. KYLE GUSTAFSON.

I am submitting my introduction of Dr. Kyle Gustafson for the American Society of Parasitologists Ashton Cuckler New Investigator Award I presented at the ASP annual meeting in Cancun Mexico a few months ago.

Michael E. DeBakey, Surgeon, Scientist, Innovator and Administrator (1908-2008).

Clinical and pathological features of myeloid leukemia cutis.

Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia.

Acute Lymphoblastic Leukemia - Diagnostics, Subgroups and Therapies.

The acute lymphoblastic leukemia (ALL) is a heterogenous rare malignant disease of lymphoblastic precursor cells. The peak of incidence lies in childhood (5.3/100 000), but the incidence rises again from the age of 50 onwards, showing a second peak at patients > 80 years old (2.3/100 000). The ALL is an acute life-threatening disease which untreated leads to death within a short time. The therapeutic objective is cure. By the characterization of subgroups, their targeted therapy and therapy optimizati...

Aligning Health Care and Academia: The Clinician Innovator.

Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?

Generic antiepileptic drugs (AED) are significantly cheaper than brand name drugs, and may reduce overall health care expenditures. Regulatory bodies in Europe and North America require bioequivalence between generic and innovator drugs with regard to area under the plasma concentration-time curve (AUC) and peak plasma concentration (C ); strict cutoff values have been defined. The main issue is if bioequivalence ensures therapeutic equivalence. Are switches from brand to generic, or between generic AEDs en...

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Nivolumab to control molecular response in chronic myeloid leukemia.

Clustered incidence of adult acute promyelocytic leukemia.

Characterization of chronic myelomonocytic leukemia with TP53 mutations.

Response kinetics and factors predicting survival in core-binding factor leukemia.

Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia.

Acute promyelocytic leukemia in the intensive care unit: A retrospective analysis.

Granular B-acute lymphoblastic leukemia: Ultrastructural characterization of cytoplasmic granules.

A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia.

TFG-RARA: A novel fusion gene in acute promyelocytic leukemia that is responsive to all-trans retinoic acid.

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.

Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia.


Advertisement
Quick Search
Advertisement
Advertisement